vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Kennedy-Wilson Holdings, Inc. (KW). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $120.6M, roughly 1.6× Kennedy-Wilson Holdings, Inc.). Kennedy-Wilson Holdings, Inc. runs the higher net margin — 48.1% vs -14.6%, a 62.7% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -11.0%). Axsome Therapeutics, Inc. produced more free cash flow last quarter ($-18.7M vs $-55.2M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -6.0%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Kennedy Wilson is a real estate investment company headquartered in Beverly Hills, California, United States.
AXSM vs KW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $120.6M |
| Net Profit | $-28.6M | $58.0M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 57.3% |
| Net Margin | -14.6% | 48.1% |
| Revenue YoY | 65.0% | -11.0% |
| Net Profit YoY | 61.9% | 32.7% |
| EPS (diluted) | $-0.55 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $120.6M | ||
| Q3 25 | $171.0M | $116.4M | ||
| Q2 25 | $150.0M | $135.7M | ||
| Q1 25 | $121.5M | $128.3M | ||
| Q4 24 | $118.8M | $135.5M | ||
| Q3 24 | $104.8M | $127.5M | ||
| Q2 24 | $87.2M | $132.0M | ||
| Q1 24 | $75.0M | $136.4M |
| Q4 25 | $-28.6M | $58.0M | ||
| Q3 25 | $-47.2M | $-10.2M | ||
| Q2 25 | $-48.0M | $5.6M | ||
| Q1 25 | $-59.4M | $-29.6M | ||
| Q4 24 | $-74.9M | $43.7M | ||
| Q3 24 | $-64.6M | $-66.8M | ||
| Q2 24 | $-79.3M | $-48.3M | ||
| Q1 24 | $-68.4M | $37.7M |
| Q4 25 | -13.8% | 57.3% | ||
| Q3 25 | -27.0% | -6.2% | ||
| Q2 25 | -24.5% | 7.4% | ||
| Q1 25 | -46.9% | -26.9% | ||
| Q4 24 | -61.1% | 36.7% | ||
| Q3 24 | -59.8% | -60.8% | ||
| Q2 24 | -89.5% | -45.5% | ||
| Q1 24 | -89.7% | 47.2% |
| Q4 25 | -14.6% | 48.1% | ||
| Q3 25 | -27.6% | -8.8% | ||
| Q2 25 | -32.0% | 4.1% | ||
| Q1 25 | -48.9% | -23.1% | ||
| Q4 24 | -63.1% | 32.3% | ||
| Q3 24 | -61.7% | -52.4% | ||
| Q2 24 | -91.0% | -36.6% | ||
| Q1 24 | -91.1% | 27.6% |
| Q4 25 | $-0.55 | $0.22 | ||
| Q3 25 | $-0.94 | $-0.15 | ||
| Q2 25 | $-0.97 | $-0.05 | ||
| Q1 25 | $-1.22 | $-0.30 | ||
| Q4 24 | $-1.54 | $0.24 | ||
| Q3 24 | $-1.34 | $-0.56 | ||
| Q2 24 | $-1.67 | $-0.43 | ||
| Q1 24 | $-1.44 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $184.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.5B |
| Total Assets | $689.8M | $6.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $184.5M | ||
| Q3 25 | $325.3M | $382.6M | ||
| Q2 25 | $303.0M | $309.1M | ||
| Q1 25 | $300.9M | $356.6M | ||
| Q4 24 | $315.4M | $217.5M | ||
| Q3 24 | $327.3M | $367.1M | ||
| Q2 24 | $315.7M | $366.5M | ||
| Q1 24 | $331.4M | $541.9M |
| Q4 25 | $88.3M | $1.5B | ||
| Q3 25 | $73.7M | $1.5B | ||
| Q2 25 | $73.1M | $1.6B | ||
| Q1 25 | $53.2M | $1.6B | ||
| Q4 24 | $57.0M | $1.6B | ||
| Q3 24 | $92.9M | $1.6B | ||
| Q2 24 | $102.9M | $1.7B | ||
| Q1 24 | $144.0M | $1.7B |
| Q4 25 | $689.8M | $6.6B | ||
| Q3 25 | $669.3M | $6.7B | ||
| Q2 25 | $639.8M | $6.8B | ||
| Q1 25 | $596.7M | $7.2B | ||
| Q4 24 | $568.5M | $7.0B | ||
| Q3 24 | $561.5M | $7.4B | ||
| Q2 24 | $548.2M | $7.5B | ||
| Q1 24 | $545.7M | $7.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $11.4M |
| Free Cash FlowOCF − Capex | $-18.7M | $-55.2M |
| FCF MarginFCF / Revenue | -9.6% | -45.8% |
| Capex IntensityCapex / Revenue | 0.0% | 55.2% |
| Cash ConversionOCF / Net Profit | — | 0.20× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $-103.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $11.4M | ||
| Q3 25 | $1.0M | $-7.6M | ||
| Q2 25 | $-32.4M | $42.0M | ||
| Q1 25 | $-43.4M | $-51.9M | ||
| Q4 24 | $-26.2M | $55.1M | ||
| Q3 24 | $-18.6M | $-5.6M | ||
| Q2 24 | $-30.1M | $36.7M | ||
| Q1 24 | $-53.5M | $-5.6M |
| Q4 25 | $-18.7M | $-55.2M | ||
| Q3 25 | $988.0K | $-18.0M | ||
| Q2 25 | $-32.4M | $29.4M | ||
| Q1 25 | $-43.7M | $-59.7M | ||
| Q4 24 | $-26.2M | $-76.5M | ||
| Q3 24 | $-18.7M | $-27.7M | ||
| Q2 24 | $-30.2M | $-500.0K | ||
| Q1 24 | $-53.6M | $-57.1M |
| Q4 25 | -9.6% | -45.8% | ||
| Q3 25 | 0.6% | -15.5% | ||
| Q2 25 | -21.6% | 21.7% | ||
| Q1 25 | -36.0% | -46.5% | ||
| Q4 24 | -22.1% | -56.5% | ||
| Q3 24 | -17.9% | -21.7% | ||
| Q2 24 | -34.6% | -0.4% | ||
| Q1 24 | -71.4% | -41.9% |
| Q4 25 | 0.0% | 55.2% | ||
| Q3 25 | 0.0% | 8.9% | ||
| Q2 25 | 0.0% | 9.3% | ||
| Q1 25 | 0.3% | 6.1% | ||
| Q4 24 | 0.0% | 97.1% | ||
| Q3 24 | 0.1% | 17.3% | ||
| Q2 24 | 0.1% | 28.2% | ||
| Q1 24 | 0.1% | 37.8% |
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 7.50× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
KW
| Consolidated Portfolio Segment | $84.9M | 70% |
| Investment Management Fees | $30.4M | 25% |
| Real Estate | $5.1M | 4% |
